Literature DB >> 10961711

Selection of lower cutoff point of [13C]urea breath test is helpful to monitor H. pylori eradication after proton pump inhibitor-based triple therapy.

B S Sheu1, S C Lee, H B Yang, A W Kuo, Y L Wang, S C Shiesh, J J Wu, X Z Lin.   

Abstract

Our objectives were to test the efficacy of [13C] urea breath test (UBT) for H. pylori infection in patients before and after proton pump inhibitor (PPI) based triple therapy, and thus to trace the optimal cutoff value of UBT to monitor H. pylori eradication; and to analyze the histologic bacterial density and distribution of H. pylori in patients with equivocal UBT. A total of 441 dyspeptic cases patients enrolled and completed the study design, including 120 noninfected and 321 H. pylori-infected patients. All 441 cases had received the same protocol of UBT. in which the baseline and 15-min gas samples after ingestion of 100 mg 13C-labeled urea were analyzed for excess 13CO2/12CO2 ratio (ECR). In addition, a first endoscopy was performed in each patient to evaluate the initial status of H. pylori by culture and histology. Of the 321 H. pylori-infected patients, 286 received a second endoscopy and a second UBT six weeks after completing any one of four regimens of the PPI-based triple therapy to document the success of H. pylori eradication. During both sessions of endoscopy, topographic gastric biopsies for histology were sampled to evaluate the distribution and density of H. pylori. Based on the diagnostic standard by culture and histology, the sensitivity and specificity of the first UBT achieved most optimally was 97.5% and 96.7%, respectively, by setting the cutoff point of ECR at 4.0. In contrast, using the same cutoff point of 4.0, the sensitivity and specificity of the second UBT in patients after therapy achieved just 80% and 97.6%, respectively. By applying cutoff points downward of 4.0, 3.5, 3, and 2.5 for the second UBT, the sensitivity was elevated to 80%, 82.8%, 88.6%, and 94.3%, respectively, while the specificity was preserved at more than 95.2%. The overall eradication rate of H. pylori was 87.8% (251/286). Seven of 35 patients with failure of therapy had equivocal ECR at the second UBT (range 2-5), and this accounted for the false negative result. All seven patients had low bacterial densities, and three patients had bacteria distributed only in high body near the cardia. In conclusion, selection of a lower cutoff value of ECR at 2.5 is helpful to maintain the diagnostic accuracy of UBT for monitoring the H. pylori eradication. The equivocal ECR of UBT after therapy would be related to the low bacterial load and its distribution.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961711     DOI: 10.1023/a:1005599818959

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  11 in total

1.  The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients.

Authors:  K E McColl; A el-Nujumi; L Murray; E el-Omar; D Gillen; A Dickson; A Kelman; T E Hilditch
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Testing for Helicobacter pylori infection after antibiotic treatment.

Authors:  P H Katelaris; D B Jones
Journal:  Am J Gastroenterol       Date:  1997-08       Impact factor: 10.864

3.  Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer.

Authors:  B S Sheu; H B Yang; I J Su; S C Shiesh; C H Chi; X Z Lin
Journal:  Gastrointest Endosc       Date:  1996-12       Impact factor: 9.427

4.  Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.

Authors:  T Lind; S Veldhuyzen van Zanten; P Unge; R Spiller; E Bayerdörffer; C O'Morain; K D Bardhan; M Bradette; N Chiba; M Wrangstadh; C Cederberg; J P Idström
Journal:  Helicobacter       Date:  1996-09       Impact factor: 5.753

5.  Clinical application of gastric histology to monitor treatment of dual therapy in H. pylori eradication.

Authors:  H B Yang; B S Sheu; I J Su; C H Chien; X Z Lin
Journal:  Dig Dis Sci       Date:  1997-09       Impact factor: 3.199

6.  Effect of standard and high dose ranitidine on [13C]urea breath test results.

Authors:  A F Cutler; M Elnaggar; E Brooks; K O'Mara
Journal:  Am J Gastroenterol       Date:  1998-08       Impact factor: 10.864

7.  Helicobacter pylori infection and the risk of gastric carcinoma.

Authors:  J Parsonnet; G D Friedman; D P Vandersteen; Y Chang; J H Vogelman; N Orentreich; R K Sibley
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

8.  [13C]urea breath test to confirm eradication of Helicobacter pylori.

Authors:  A Slomianski; T Schubert; A F Cutler
Journal:  Am J Gastroenterol       Date:  1995-02       Impact factor: 10.864

Review 9.  Urea breath tests in the management of Helicobacter pylori infection.

Authors:  R P Logan
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

Review 10.  The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.

Authors:  J H Walsh; W L Peterson
Journal:  N Engl J Med       Date:  1995-10-12       Impact factor: 91.245

View more
  8 in total

1.  Posttreatment 13C-urea breath test is predictive of antimicrobial resistance to H. pylori after failed therapy.

Authors:  Ai-Wen Kao; Hsiu-Chi Cheng; Bor-Shyang Sheu; Ching-Yih Lin; Ming-Jen Sheu; Hsiao-Bai Yang; Jiunn-Jong Wu
Journal:  J Gen Intern Med       Date:  2005-02       Impact factor: 5.128

2.  No difference of accuracy between capillary and venous blood in rapid whole blood test for diagnosis of Helicobacter pylori infection.

Authors:  Tseng-Shing Chen; Full-Young Chang; Shou-Dong Lee
Journal:  Dig Dis Sci       Date:  2002-11       Impact factor: 3.199

3.  Pretreatment gastric histology is helpful to predict the symptomatic response after H. pylori eradication in patients with nonulcer dyspepsia.

Authors:  B S Sheu; H B Yang; Y L Wang; C H Chuang; A H Huang; J J Wu
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

4.  Are dyspeptic symptoms linked to Helicobacter pylori? A prospective cohort study among medical students.

Authors:  Karl M Hoffmann; Andreas J Eherer; Günter J Krejs
Journal:  Wien Klin Wochenschr       Date:  2003-03-31       Impact factor: 1.704

5.  An optimized 13C-urea breath test for the diagnosis of H pylori infection.

Authors:  Germán Campuzano-Maya
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

Review 6.  Antibiotic treatment for Helicobacter pylori: Is the end coming?

Authors:  Su Young Kim; Duck Joo Choi; Jun-Won Chung
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

7.  Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale.

Authors:  Bor-Shyang Sheu; Ming-Shiang Wu; Cheng-Tang Chiu; Jing-Chuan Lo; Deng-Chyang Wu; Jyh-Ming Liou; Chun-Ying Wu; Hsiu-Chi Cheng; Yi-Chia Lee; Ping-I Hsu; Chun-Chao Chang; Wei-Lun Chang; Jaw-Town Lin
Journal:  Helicobacter       Date:  2017-01-08       Impact factor: 5.753

Review 8.  Non-invasive diagnostic tests for Helicobacter pylori infection.

Authors:  Lawrence Mj Best; Yemisi Takwoingi; Sulman Siddique; Abiram Selladurai; Akash Gandhi; Benjamin Low; Mohammad Yaghoobi; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.